TheranosticTrials.org

Clinical Trial · NCT04221061

18F-FluorThanatrace (PET/CT) in Glioblastoma

Overview

The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).

Sponsor

University of Pennsylvania

Phase

Early Phase 1

Contacts

Austin R Pantel, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04221061

Drug / Compound

FluorThanatrace

Isotope(s):
Target(s):
  • PARP
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Participants will have a diagnosis of glioblastoma and be enrolled in the companion treatment trial, IRB 832694.

Exclusion

  • Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential at screening.
  • Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study